Positioning Statements on Physician-led Switching for Biosimilar Medicines


Positioning statements on physician-led switching for biosimilar medicines (October 2021)


Biosimilar medicines group position on physician-led switching (July 2015)


Biosimilar medicines group position on biologic pharmacy substitution (September 2020)

Position Paper. Incentives Review The Orphan and Paediatric Incentives

Electronic product information: from principles to actions. AESGP, EFPIA and Medicines for Europe reflections on EMAHMA – EC Key principles for electronic product information

Open

Biosimilars in the EU – Information guide for healthcare professionals – unofficial Ukrainian translation now available

Open unofficial Ukrainian translation

Filling the gap: How off-patent medicines can improve the equity and quality of cancer care

Open

Filling the gap: How off-patent medicines can improve the equity and quality of cancer care

Open

The total clinical experience with biosimilar medicines exceeds 2 billion patient treatment days

Biosimilar medicines are available in therapy areas which represent 65% of the biologics market by value

In Europe, biosimilar medicines have captured 7% more of the biologics market over a 5-year period

Growing number of biologic therapies offers future opportunities for biosimilar development

Medicines For Europe